Aqur Biosciences Featured in DelveInsight’s 2025 PCSK9 Inhibitor Market Report for Its Innovative Oral Cholesterol-Lowering Therapy
WESTLAKE VILLAGE, Calif. – Aqur Biosciences, Inc. (“Aqur” or the “Company”), a bioscience company dedicated to pioneering next-generation cardiovascular therapies, today announced its inclusion in DelveInsight’s 2025 report, “PCSK9 Inhibitors Market: Current Landscape and Market Forecast (2023–2034).”
New Appointments to Our Scientific Advisory Board: Welcoming Professor Khaled Machaca and Dr. George Tsoukas
We are pleased to announce the appointment of two distinguished experts to our Scientific Advisory Board: Professor Khaled Machaca, PhD, and Dr. George M. Tsoukas, MD, FRCPC.
Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, today announced a definitive agreement for Lilly to acquire Verve.
Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the first two of three Phase 3 clinical trials evaluating the safety and efficacy of enlicitide decanoate, an investigational, oral proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor being evaluated for the treatment of adults with hyperlipidemia on lipid-lowering therapies, including at least a statin.
Aqur Biosciences Reinvents Its Look — and the Future of Cholesterol Care
Aqur Biosciences, Inc. (“Aqur” or the “Company”), a bioscience company dedicated to pioneering next-generation cardiovascular therapies, is proud to announce the launch of its new brand identity — a reflection of the Company’s renewed strategic focus, innovative pipeline, and unwavering commitment to transforming patient care.
Verve’s 2nd swing at PCSK9 editing yields clean safety profile, teeing up Lilly opt-in decision.
Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. One year after dropping a base editing candidate over a safety signal, the biotech has shown its Eli Lilly-partnered successor can achieve similar cholesterol reductions without raising any red flags.
AstraZeneca – AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
Positive results from the PURSUIT Phase IIb trial for AstraZeneca’s AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol (LDL-C) reduction when administered on top of standard-of-care statin therapy, as compared with placebo. AZD0780 is an investigational once-daily oral PCSK9 inhibitor for patients currently not reaching their LDL-C lowering goal despite standard-of-care lipid-lowering therapies such as statins.
Oral and Non-Oral Cholesterol-Lowering Drugs with PCSK9 and Other Biomolecules as Targets: Present Status and Future Prospects.
A recent article published by PhD Ajoy Basak in Biomolecules delves into the current landscape of cholesterol-lowering treatments, focusing on both oral and non-oral medications targeting PCSK9 and other biomolecules. The review assesses the efficacy, mechanisms, and future prospects of these therapies in managing hypercholesterolemia and cardiovascular diseases.
PCSK9 Inhibitors Market Anticipate to Accelerate in the Coming 10 Years Owing to the Increasing Demand for Innovative Cholesterol-Lowering Drugs | DelveInsight
The PCSK9 inhibitor market is projected to experience substantial growth due to its use in statin-intolerant patients, emerging strategies for PCSK9 inhibition, its potential applications across broader therapeutic areas, and its role in prophylactic treatment, which could help alleviate the burden of cardiovascular disease.
Emerging oral therapeutic strategies for inhibiting PCSK9.
A recent article by Dr. Nicola Ferri (University of Padova, Italy) and PhD student Giorgia Marodin, published in Atherosclerosis Plus journal, highlights the significant progress in the pharmacological inhibition of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9). This therapeutic strategy has been firmly established as an effective approach to lowering low-density lipoprotein (LDL) cholesterol levels and reducing the risk of cardiovascular events.
